John W. Elling

Vista Therapeutics, Inc. develops nanotechnology for multiplex biomarker measurement. Its NanoBioSensor technology provides continuous, real-time measurement of multiple biomarkers simultaneously in any clinical setting. The firm's technology can be used to improve the quality of animal data in drug development. The company was founded by Spencer W. Farr and Charles M. Lieber in 2007 and is headquartered in Santa Fe, NM.

GPER G-1 Development Group LLC is a company that has developed a novel therapeutic called G-1 (Tespria) for the treatment of diabetes and obesity. Approximately one third of the population is either diabetic or pre-diabetic, and the estimated economic burden of diabetes in the US in 2017 was over $300 billion. The company is based in Albuquerque, NM. The company aims to target metabolic activity in "brown fat" cells to treat these conditions. G-1 (Tespria) has minimal competition and is revolutionary in that it modulates energy expenditure in the absence of changes in food intake or activity. The company was founded by John J. Chavez, and the CEO is John W. Elling.

Founded in 1997, Chicago-based Integrated Genomics™ specializes in research in microbial genomics, biochemistry, and gene expression. Its scientists has broad experience in both in silico and wet lab sequencing, research and development with more than 100 relevant publications in these areas. Integrated Genomics™ has particularly long-standing relationships and active research in the area of lactic acid bacteria and pathogenic microbes, as well as a broad customer base across industry, academic and government institutions. Integrated Genomics™' products and services are based on ERGO™, its web-based genome analysis platform. ERGO™ integrates proprietary functional genomic data, metabolic reconstructions, expression profiling, and biochemical and microbiological data with publicly available information. Focused on microbial genomics, ERGO™ provides better and faster identification of gene function across all organisms. In 2010 Integrated Genomics, Inc.'s business operations were transitioned to a new corporation, IG Assets, Inc. With the original Integrated Genomics' team, IG Assets continues to provide the same ERGO-based microbial genomic products and service.

Greffen Systems, Inc. provides HVAC industrial solutions. It offers design, project management, installation, testing and ongoing product services. The firm specializes in UV-C germicidal lighting, upper air fixtures, M2G and infection control solution. The company was founded in 2008 and is headquartered in Dawsonville, GA.

Mitotech LLC develops medical nanotechnology solutions. The firm's pipeline has a number of drug candidates based on mitochondria-addressed antioxidant. Its specialties include nanobiotechnology, drug development, research and development in biology and medicine. The company was founded by Maxim Skulachev and John W. Elling in 2009 and is headquartered in Moscow, Russia.

xF Technologies, Inc. engages as a technology development company which produces non-toxic specialty chemicals. Its chemical applications include cleaning and processing solvents, plasticizers, coalescents , and personal care. The company was founded by Jacob Berman and Aviad Cahana in January 2007 and is headquartered in Moriarty, NM.

IG Assets products and services are based on ERGO, its web-based genome analysis platform. ERGO integrates proprietary functional genomic data, metabolic reconstructions, expression profiling, and biochemical and microbiological data with publicly available information. Focused on microbial genomics, ERGO provides better and faster identification of gene function across all organisms. Its scientists have broad experience in both in silico and wet lab sequencing, research and development with more than 100 relevant publications in these areas.